Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.43
+0.3%
$3.34
$2.57
$6.88
$21.20M0.629,053 shs1,758 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.61
-4.1%
$0.62
$0.24
$4.37
$20.12M0.59968,004 shs256,584 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$8.18
+1.9%
$7.46
$3.34
$16.50
$22.78M1.0933,035 shs6,653 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.18
-40.4%
$0.65
$0.20
$3.10
$3.08M0.92278,076 shs3.73 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.59%+3.01%-1.13%+24.36%-39.25%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
+0.72%+3.59%-9.74%+116.44%-83.54%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-4.24%+13.34%+5.65%+65.52%-9.92%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%-10.54%-77.57%-81.20%-88.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4542 of 5 stars
0.04.00.00.03.31.70.6
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.7406 of 5 stars
3.15.00.04.41.94.21.3
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.1742 of 5 stars
3.55.00.00.02.21.70.6
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
4.6487 of 5 stars
3.35.00.04.74.40.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00724.67% Upside
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.00
Buy$40.00389.30% Upside
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
2.50
Moderate Buy$3.751,994.97% Upside

Current Analyst Ratings Breakdown

Latest UBX, NAII, SLGL, and RLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$4.00 ➝ $2.00
5/16/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$6.00 ➝ $1.00
4/23/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/23/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$12.10M1.88N/AN/A$10.36 per share0.79
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%7/22/2025 (Estimated)

Latest UBX, NAII, SLGL, and RLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25N/AN/AN/AN/AN/A
8/5/2025Q2 2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$0.30N/AN/AN/AN/AN/A
5/23/2025Q1 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A-$3.20N/A-$3.20N/A$1.03 million
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
4/22/2025Q1 2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$0.43-$0.43N/A-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
5.29
5.29
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
5.12
5.12
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95
CompanyEmployeesShares OutstandingFree FloatOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable

Recent News About These Companies

UBX Unity Biotechnology, Inc. - Seeking Alpha
Unity Biotechnology price target lowered to $4 from $6 at Chardan
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

New MarketBeat Followers Over Time

Media Sentiment Over Time

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.41 -0.01 (-0.41%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.61 -0.03 (-4.07%)
Closing price 04:00 PM Eastern
Extended Trading
$0.63 +0.02 (+3.91%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$8.18 +0.16 (+1.93%)
Closing price 03:57 PM Eastern
Extended Trading
$8.18 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

$0.18 -0.12 (-40.43%)
Closing price 07/8/2025
Extended Trading
$0.18 0.00 (0.00%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.